These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 21927578)
1. IL-10-IFN-γ double producers CD4+ T cells are induced by immunization with an amastigote stage specific derived recombinant protein of Trypanosoma cruzi. Flores-García Y; Rosales-Encina JL; Satoskar AR; Talamás-Rohana P Int J Biol Sci; 2011; 7(8):1093-100. PubMed ID: 21927578 [TBL] [Abstract][Full Text] [Related]
2. Antigen-specific Il-4- and IL-10-secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection. Barbosa de Oliveira LC; Curotto de Lafaille MA; Collet de Araujo Lima GM; de Almeida Abrahamsohn I Cell Immunol; 1996 May; 170(1):41-53. PubMed ID: 8660798 [TBL] [Abstract][Full Text] [Related]
4. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. Gupta S; Garg NJ PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586 [TBL] [Abstract][Full Text] [Related]
5. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. de Alencar BC; Persechini PM; Haolla FA; de Oliveira G; Silverio JC; Lannes-Vieira J; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM Infect Immun; 2009 Oct; 77(10):4383-95. PubMed ID: 19651871 [TBL] [Abstract][Full Text] [Related]
6. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554 [TBL] [Abstract][Full Text] [Related]
7. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671 [TBL] [Abstract][Full Text] [Related]
9. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Rodrigues MM; Ribeirão M; Pereira-Chioccola V; Renia L; Costa F Infect Immun; 1999 Aug; 67(8):3855-63. PubMed ID: 10417149 [TBL] [Abstract][Full Text] [Related]
10. Immunization of mice with a TolA-like surface protein of Trypanosoma cruzi generates CD4(+) T-cell-dependent parasiticidal activity. Quanquin NM; Galaviz C; Fouts DL; Wrightsman RA; Manning JE Infect Immun; 1999 Sep; 67(9):4603-12. PubMed ID: 10456906 [TBL] [Abstract][Full Text] [Related]
11. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi. Gupta S; Garg NJ Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191 [TBL] [Abstract][Full Text] [Related]
12. Experimental Nanovaccine Offers Protection Against Repeat Exposures to Chowdhury IH; Lokugamage N; Garg NJ Front Immunol; 2020; 11():595039. PubMed ID: 33414785 [TBL] [Abstract][Full Text] [Related]
13. Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi. Wrightsman RA; Manning JE Vaccine; 2000 Jan; 18(14):1419-27. PubMed ID: 10618540 [TBL] [Abstract][Full Text] [Related]
14. The surface protein superfamily of Trypanosoma cruzi stimulates a polarized Th1 response that becomes anergic. Millar AE; Wleklinski-Lee M; Kahn SJ J Immunol; 1999 May; 162(10):6092-9. PubMed ID: 10229851 [TBL] [Abstract][Full Text] [Related]
15. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM Front Immunol; 2020; 11():1279. PubMed ID: 32695105 [TBL] [Abstract][Full Text] [Related]
16. Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine. Rosas-Jorquera CE; Sardinha LR; Pretel FD; Bombeiro AL; D'Império Lima MR; Alvarez JM Clin Vaccine Immunol; 2013 Feb; 20(2):248-54. PubMed ID: 23254299 [TBL] [Abstract][Full Text] [Related]
17. The SA85-1.1 protein of the Trypanosoma cruzi trans-sialidase superfamily is a dominant T-cell antigen. Millar AE; Kahn SJ Infect Immun; 2000 Jun; 68(6):3574-80. PubMed ID: 10816514 [TBL] [Abstract][Full Text] [Related]
18. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection. Schnapp AR; Eickhoff CS; Scharfstein J; Hoft DF Microbes Infect; 2002 Jul; 4(8):805-13. PubMed ID: 12270727 [TBL] [Abstract][Full Text] [Related]